ADENOSINE INJECTION

The Defense Logistics Agency awarded a firm-fixed-price delivery order, SPE2DP26F7879, to DMS PHARMACEUTICAL GROUP INC (CAGE 1UNB0) for the supply of 6 units of ADENOSINE INJECTION (NSN 6505016660343, NDC 25021-0301-68) under the base contract SPE2DX25D9900, with a total value of $1,388.70. The award, issued on July 21, 2026, requires delivery to JBER, Alaska, with FOB destination terms placing transportation and risk responsibility on the contractor. Payment is set at Net 30 days, with invoicing mandated through the WAWF system in accordance with DFARS 252.232-7003 and processed by DFAS Columbus. The awardee is certified as a Small, Women-Owned Small Business, with representations and certifications reflected in the delivery order. The product must conform to applicable contract terms, with inspection and acceptance performed by government personnel at the delivery location. Packaging and marking requirements reference DLA procedural notes C19 and C20 for transportation and unit-of-issue compliance, though no explicit MIL-STDs or detailed labeling standards are provided. The contract contains no option periods, special requirements, or additional line items, and no formal contract clauses or attachments are included in the documentation, with all terms incorporated by reference from the underlying base contract. Contract administration is handled by Lisa Quinn, the Ordering Officer, and Shairy M. Cartagena of DLA Troop Support’s Medical Supply Chain Pharm FSA.